Osteoporosis: Mechanism of Therapeutic Action of Bisphosphonates and Clinical Perspectives

N.V. Dedukh

Abstract


This article describes the effects of bisphosphonates in increasing the strength of the structure and quality of the bone, special attention is paid to ibandronate. The review of multi-center clinical trials of ibandronate efficacy in women with postmenopausal osteoporosis is given. Data from these studies suggest that prolonged use of ibandronate in complex treatment of postmenopausal osteoporosis leads not only to a progressive increase in bone mineral density at the lumbar spine and proximal femur, but to decrease in markers of bone resorption and increased bone quality.


Keywords


osteoporosis; postmenopause; treatment; ibandronate

References


Efficasy end tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the ­MOBILE study / J.Y. Reginster, S. Adami, P. Lakatos et al. // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 654-661.

Reginster J.Y. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis / J.Y. Reginster, R. Gieschke // Curr. Drug Metab. — 2006. — Vol. 7. — P. 827-836.

Nguyen T.V. Osteoporosis: underrated, underdiagnosed and undertreated / T.V Nguyen, J.R Center, J.A. Eisman // MJA. — 2004. — Vol. 180. — S18-S22.

Riggs B.L. A unitary model for involutional osteoporosisestrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men / B.L. Riggs, S. Khosla, L.I. Melton // J. Bone Miner. Res. — 1998. — Vol. 13. — P. 763-773.

Rogers M.J. New insights into molecular mechanisms of action of bisphosphonates / M.J. Rogers // Curr. Pham. Des. — 2003. — Vol. 9. — Р. 2643-2458.

Papapoulos S.E. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate / S.E. Papapoulos, R.C. Schimmer // Ann. Rheum. Dis. — 2007. — Vol. 66. — P. 853-858.

Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausаl osteoporosis / S.E. Papapoulos // IJCP. — 2003. — Vol. 57. — P. 417-422.

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy / R.G. Russell, Z. Xia, J.E. Dunford et al. // Ann. NY Acad. Sci. — 2007. — Vol. 1117. — P. 209-257.

Bone safety of long-term bisphosphonate treatment / G. Rodan, A. Reszka, E. Golub, R. Rizzoli // Curr. Med. Res. Opin. — 2004. — Vol. 20, № 8. — P. 1291-1300.

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption / R.C. Muаhlbauer, F. Bauss, R. Schenk et al. // J. Bone Miner. Res. — 1991. — Vol. 6. — P. 1003-1011.

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS / S.P. Luckman, D.E. Hughes, F.P. Coxon et al. // J. Bone Miner. Res. — 1998. — Vol. 13. — P. 581-589.

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates / J.E. Dunford, K. Thompson, F.P. Coxon et al. // J. Pharmacol. Exp. Ther. — 2001. — Vol. 296. — P. 235-242.

Rodan G.A. Bisphosphonate Mechanism of Action / G.A. Rodan, A.A. Reszka // Current Molecular Medicine. — 2002. — Vol. 2. — P. 571-577.

Bisphosphonates: effects on osteoblast / N. Maruotti, A. Corrado, A. Neve, F.P. Cantatore // Eur. J. Clin. Pharmacol. — 2012. — Vol. 68, № 7. — P. 1013-1018.

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner — a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2 / F.P. Koch, C. Merkel, B. Al-Nawas et al. // J. Craniomaxillofac. Surg. — 2011. — Vol. 39, № 8. — P. 562-569.

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin / L.I. Plotkin, R.S. Weinstein, A.M. Parfitt et al. // J. Clin. Invest. — 1999. — Vol. 104. — P. 1363-1374.

Ibandronate: a clinical pharmacological and pharmacokinetic update / J. Barrett, E. Worth, F. Bauss, S. Epstein // J. Clin. Pharmacol. — 2004. — Vol. 44. — P. 951-65.

Ibandronate in the Management of Postmenopausal Osteoporosis / J.Y. Reginster, M. Hiligsmann, V. Rabenda et al. // Clinical Medicine: Therapeutics. — 2009. — Vol. 1. — Р. 1409-1421.

Russell R.G.G. Ibandronate: pharmacology and preclinical studies / R.G.G. Russell // Bone. — 2006. — Vol. 38. — P. 7-12.

Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties / M.C. Monier-Faugere, Z. Geng, E.P. Paschalis et al. // J. Bone Miner. Res. — 1999. — Vol. 14. — P. 1768-1778.

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis / B.J. Riis, J. Ise, von T. Stein et al. // J. Bone Miner. Res. — 2001. — Vol. 16. — P. 1871-1878.

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis / C. Cooper, R.D. Emkey, R.H. McDonald et al. // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88. — P. 4609-4615.

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1 year results from the MOBILE study / P.D. Mil­ler, M. McClung, I. Macovei et al. // J. Bone Miner. Res. — 2005. — Vol. 20. — P. 1315-1322.

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension / J.A. Stakkestad, P. Lakatos, R. Lorenc, F. Sedarati, C. Neate, J.Y. Reginster // Clin. Rheumatol. — 2008. — Vol. 27, № 8. — P. 955-960.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE / C.H. Chesnut, M.P. Ettinger, P.D. Miller et al. // Curr. Med. Res. Opin. — 2005. — Vol. 21, № 3. — P. 391-401.

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study / R.R. Recker, R.S. Weinstein, C.H. Chesnut et al. // Osteoporos Int. — 2004. — Vol. 15, № 3. — P. 231-237.

Oncemonthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study / P.D. Miller, S. Epstein, F. Sedarati, J.Y. Reginster // Curr. Med. Res. Opin. — 2008. — Vol. 24. — P. 207-213.

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomised, open-label, crossover trial: the Bonviva Alendronate trial in osteoporosis // Curr. Med. Res. Opin. — 2005. — Vol. 21. — P. 1895-1903.

Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products / H.J. Lehmann, U. Mouritzen, S. Christgau et al. // Ann. Rheum. Dis. — 2002. — Vol. 61. — P. 530-533.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study / R. Emkey, P.D. Delmas, M. Bolognese et al. // Clin. Ther. — 2009. — Vol. 31, № 4. — P. 751-761.

Bianchi G. Long-term administration of quarterly IY ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension / G. Bianchi, E. Czerwinski, A. Kenwright et al. // Osteopor. Int. — 2011.

Eisman J.A. Intermittent intravenous ibandronate injections are an effective treatment in postmenopausal osteoporosis: 2-year results from DIVA / J.A. Eisman, P.A. Garcia-Hernandez, G. Ortiz-Luna et al. // Osteoporos. Int. — 2006. — Vol. 17, Suppl. 2. — SS. 212.




DOI: https://doi.org/10.22141/1608-1706.2.14.2013.88581

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru